Halozyme Therapeutics HALO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating income?
- Halozyme Therapeutics (HALO) reported operating income of $184.52M in Q1 2026.
- How has Halozyme Therapeutics's operating income changed year-over-year?
- Halozyme Therapeutics's operating income increased by 30.4% year-over-year, from $141.54M to $184.52M.
- What is the long-term trend for Halozyme Therapeutics's operating income?
- Over 3 years (2021 to 2024), Halozyme Therapeutics's operating income has grown at a 26.0% compound annual growth rate (CAGR), from $275.9M to $551.48M.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.
- How do you interpret operating income?
- Higher operating income indicates strong operational performance and effective cost management.
- How does operating income compare across companies?
- A key performance indicator for all public companies; biotech companies often have negative operating income during early-stage development.